Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

被引：7

作者：

Cohen, Jonathon B. ^{[1
]}

Kuruvilla, John ^{[2
,3
]}

Engert, Andreas ^{[4
]}

Ansell, Stephen M. ^{[5
]}

Younes, Anas ^{[6
]}

Lee, Hun Ju ^{[7
]}

Trneny, Marek ^{[8
,9
]}

Savage, Kerry J. ^{[10
]}

Ramchandren, Radhakrishnan ^{[11
]}

Collins, Graham P. ^{[12
]}

Zinzani, Pier Luigi ^{[13
]}

De Boer, Jan Paul ^{[14
]}

Shipp, Margaret A. ^{[15
]}

Santoro, Armando ^{[16
]}

Timmerman, John M. ^{[17
]}

Sacchi, Mariana ^{[18
]}

Sy, Oumar ^{[18
]}

Armand, Philippe ^{[19
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Univ Toronto, Toronto, ON, Canada

[3] Princess Margaret Canc Ctr, Toronto, ON, Canada

[4] Univ Hosp Cologne, Cologne, Germany

[5] Mayo Clin, Rochester, MN USA

[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Charles Univ Prague, Prague, Czech Republic

[9] Gen Univ Hosp Prague, Prague, Czech Republic

[10] British Columbia Canc, Vancouver, BC, Canada

[11] Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[12] Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England

[13] Univ Bologna, Inst Hematol L e A Seragnoli, Bologna, Italy

[14] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands

[15] Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA

[16] Humanitas Univ, Humanitas Canc Ctr, Rozzano Milan, Italy

[17] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

[18] Bristol Myers Squibb, Princeton, NJ USA

[19] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-114502

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2932

引用

页数：4

共 50 条

[1] Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 205 Study
Cohen, J. B.
Engert, A.
Ansell, S. M.
Younes, A.
Trneny, M.
Savage, K. J.
Ramchandren, R.
Collins, G. P.
Fanale, M. A.
Armand, P.
Zinzani, P. L.
de Boer, J. P.
Shipp, M. A.
Santoro, A.
Timmerman, J. M.
Sacchi, M.
Sy, O.
Kuruvilla, J.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 87 - 88
[2] Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study
Cohen, Jonathon B.
Engert, Andreas
Ansell, Stephen M.
Younes, Anas
Trneny, Marek
Savage, Kerry J.
Ramchandren, Radhakrishnan
Collins, Graham
Fanale, Michelle A.
Armand, Philippe
Zinzani, Pier Luigi
De Boer, Jan Paul
Shipp, Margaret A.
Santoro, Armando
Timmerman, John M.
Sacchi, Mariana
Sy, Oumar
Kuruvilla, John
BLOOD, 2017, 130
[3] Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
Timmerman, John M.
Engert, Andreas
Younes, Anas
Santoro, Armando
Armand, Philippe
Fanale, Michelle A.
Collins, Graham P.
Ratanatharathorn, Voravit
Kuruvilla, John
Cohen, Jonathon B.
Savage, Kerry J.
Trneny, Marek
De Boer, Jan Paul
Shipp, Margaret A.
Rodig, Scott J.
Kato, Kazunobu
Sumbul, Anne
Ansell, Stephen
BLOOD, 2016, 128 (22)
[4] Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center
Momotow, Jesko
Goergen, Helen
Behringer, Karolin
Broeckelmann, Paul J.
Borchmann, Sven
Tresckow, Bastian V.
Kobe, Carsten
Engert, Andreas
Sasse, Stephanie
HEMASPHERE, 2019, 3 (05):
[5] Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Haematopoietic Cell Transplantation: Extended Follow-Up of the Phase 2 Multi-Cohort CheckMate 205 Study
Collins, G.
Armand, P.
Engert, A.
Younes, A.
Lee, H. J.
Santoro, A.
Zinzani, P. L.
Timmerman, J.
Ramchandren, R.
Cohen, J.
De Boer, J. P.
Savage, K.
Kuruvilla, J.
Trneny, M.
Shipp, M.
Sacchi, M.
Sumbul, A.
Ansell, S.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 80 - 81
[6] NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE MULTICOHORT MULTICENTER PHASE 2 CHECKMATE 205 TRIAL
Engert, A.
Fanale, M.
Santoro, A.
Armand, P.
Ansell, S.
Zinzani, P. L.
Timmerman, J.
Collins, G.
Ramchandren, R.
Cohen, J.
De Boer, J. P.
Kuruvilla, J.
Savage, K.
Trneny, M.
Rodig, S.
Shipp, M.
Kato, K.
Sumbul, A.
Farsaci, B.
Younes, A.
HAEMATOLOGICA, 2017, 102 : 145 - 145
[7] Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow-up of the multicohort, multicenter phase 2 CheckMate 205 trial
Jaeger, U.
Engert, A.
Fanale, M.
Santoro, A.
Armand, P.
Ansell, S.
Zinzani, P. L.
Timmerman, J. M.
Collins, G. P.
Ramchandren, R.
Cohen, J. B.
De Boer, J. P.
Kuruvilla, J.
Savage, K. J.
Trneny, M.
Rodig, S.
Shipp, M.
Kato, K.
Sumbul, A.
Farsaci, B.
Younes, A.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 13 - +
[8] Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
Ansell, Stephen M.
Brockelmann, Paul J.
von Keudell, Gottfried
Lee, Hun Ju
Santoro, Armando
Zinzani, Pier Luigi
Collins, Graham P.
Cohen, Jonathon B.
de Boer, Jan Paul
Kuruvilla, John
Savage, Kerry J.
Trneny, Marek
Provencio, Mariano
Jaeger, Ulrich
Willenbacher, Wolfgang
Wen, Rachael
Akyol, Alev
Mikita-Geoffroy, Joanna
Shipp, Margaret A.
Engert, Andreas
Armand, Philippe
BLOOD ADVANCES, 2023, 7 (20) : 6266 - 6274
[9] Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study
Armand, Philippe
Engert, Andreas
Younes, Anas
Lee, Hun Ju
Santoro, Armando
Zinzani, Pier Luigi
Timmerman, John M.
Collins, Graham P.
Ramchandren, Radhakrishnan
Cohen, Jonathon B.
De Boer, Jan Paul
Savage, Kerry J.
Kuruvilla, John
Trneny, Marek
Shipp, Margaret A.
Sacchi, Mariana
Ansell, Anne Sumbuland Stephen M.
Ansell, Stephen M.
BLOOD, 2018, 132
[10] TREATMENT-RELATED ADVERSE EVENTS WITH NIVOLUMAB IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: RESULTS FROM A COHORT ANALYSIS OF THE PHASE 2 CHECKMATE 205 STUDY.
Wesson, Emily
Klebig, Robin
Stephans, Katherine
Palmer, Alexandra
Kurosky, Alanna
Copeland, Amanda
ONCOLOGY NURSING FORUM, 2017, 44 (02)

← 1 2 3 4 5 →